Niv Edward Caviar
Directeur Général chez SpineOvations, Inc.
Profil
Niv Edward Caviar currently works at SpineOvations, Inc., as Chief Executive Officer from 2014.
Mr. Caviar also formerly worked at Suneva Medical, Inc., as President & Chief Executive Officer in 2010, Affymetrix, Inc., as Director-Corporate Development from 1999 to 2001, Kalologie Skincare LLC, as Director, Allergan, Inc., as VP & Head-Marketing-Medical Dermatology Business from 2002 to 2007, La Jolla Pharmaceutical Co., as CFO, Chief Business Officer & Executive VP in 2009, iTherX Pharmaceuticals, Inc., as Vice President-Business Development & Marketing from 2001 to 2002, Humanigen, Inc., as Head-Corporate & Business Development, Air Force Space Command, as Project Manager, and US Air Force, as Engineer-Solid Rocket Motor.
Mr. Caviar received his Masters Business Admin degree from Harvard University and undergraduate degree from United States Air Force Academy.
Postes actifs de Niv Edward Caviar
| Sociétés | Poste | Début |
|---|---|---|
SpineOvations, Inc.
 SpineOvations, Inc. Medical SpecialtiesHealth Technology SpineOvations, Inc. operates as a clinical-stage medical device company. It develops therapies to treat low back pain. The company was founded by Neville Alleyne and is headquartered in Carlsbad, CA. | Directeur Général | 01/01/2014 |
Anciens postes connus de Niv Edward Caviar
| Sociétés | Poste | Fin |
|---|---|---|
| HUMANIGEN, INC. | Corporate Officer/Principal | 01/09/2017 |
iTherX Pharmaceuticals, Inc.
 iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services iTherX is a clinical stage pharmaceutical company focused on the discovery and development of innovative treatments for Hepatitis C. This is a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated. The company continues to carry out focused research in their areas of expertise to provide sustainability of product pipelines. In an era of managed care and increased regulatory scrutiny, it is easy to yield to the temptation of producing 'me too drugs'. However, they think that innovation in the development of pharmaceutical products is important because it is the only way to improve the outcomes for patients. As such, they also think that innovation can ensure the financial returns that investors in health care deserve for the risks that they take. Their innovative approach is evident in their pipeline of Hepatitis C drug candidates. As new and better treatments are being sought, most companies involved in this effort are targeting the enzymes responsible for viral replication: polymerases and proteases. While these are important targets, there is a great deal of duplication of effort in these initiatives. At iTherX, they are pioneering the development of a novel class of HCV antivirals by targeting the steps involved in the entry of the hepatitis C virus into liver cells. Their Host Cell Receptor Target Program engenders small molecule compounds that target a liver cell membrane protein, SR-B1, which recognize and dock the virus. Their lead compound, ITX5061, has extensive safety data in over 250 patients, and shows picomolar potency in inhibiting HCV infection in vitro. They plan to initiate a Phase 2a clinical trial in HCV patients in Q2 of 2009. They have also used medicinal chemistry to develop back-up compounds for this program, and a clinical candidate has been selected for development. Another innovative program is novel cell receptor, which develops antagonists (including biologics) against a novel liver cell membrane protein required for infectivity of the virus. | Sales & Marketing | 01/01/2002 |
Suneva Medical, Inc.
 Suneva Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Suneva Medical, Inc. develops, manufactures and commercializes novel, differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. It offers ArteFill, ReFissa, Bellafill, and ReGenica Skincare products. The company is headquartered in San Diego, CA. | President | 16/10/2010 |
| LA JOLLA PHARMACEUTICAL COMPANY | Directeur Financier/CFO | 25/04/2009 |
| ALLERGAN, INC. | Sales & Marketing | 01/01/2007 |
Formation de Niv Edward Caviar
| Harvard University | Masters Business Admin |
| United States Air Force Academy | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HUMANIGEN, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Allergan, Inc.
 Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Affymetrix, Inc.
 Affymetrix, Inc. Medical SpecialtiesHealth Technology Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA. | Health Technology |
iTherX Pharmaceuticals, Inc.
iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services iTherX is a clinical stage pharmaceutical company focused on the discovery and development of innovative treatments for Hepatitis C. This is a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated. The company continues to carry out focused research in their areas of expertise to provide sustainability of product pipelines. In an era of managed care and increased regulatory scrutiny, it is easy to yield to the temptation of producing 'me too drugs'. However, they think that innovation in the development of pharmaceutical products is important because it is the only way to improve the outcomes for patients. As such, they also think that innovation can ensure the financial returns that investors in health care deserve for the risks that they take. Their innovative approach is evident in their pipeline of Hepatitis C drug candidates. As new and better treatments are being sought, most companies involved in this effort are targeting the enzymes responsible for viral replication: polymerases and proteases. While these are important targets, there is a great deal of duplication of effort in these initiatives. At iTherX, they are pioneering the development of a novel class of HCV antivirals by targeting the steps involved in the entry of the hepatitis C virus into liver cells. Their Host Cell Receptor Target Program engenders small molecule compounds that target a liver cell membrane protein, SR-B1, which recognize and dock the virus. Their lead compound, ITX5061, has extensive safety data in over 250 patients, and shows picomolar potency in inhibiting HCV infection in vitro. They plan to initiate a Phase 2a clinical trial in HCV patients in Q2 of 2009. They have also used medicinal chemistry to develop back-up compounds for this program, and a clinical candidate has been selected for development. Another innovative program is novel cell receptor, which develops antagonists (including biologics) against a novel liver cell membrane protein required for infectivity of the virus. | Distribution Services |
Kalologie Skincare LLC
 Kalologie Skincare LLC Household/Personal CareConsumer Non-Durables Kalologie Skincare LLC provides skincare products and services. It offers erase lines and wrinkles, laser hair removal and rejuvenate solutions. The firm also provides cosmetic dermatology treatments, medicine and skin care consultation services. The company was founded by Tracy Brennan and William L. Brennan in 2003 and is headquartered in Santa Monica, CA. | Consumer Non-Durables |
| Air Force Space Command | Government |
| US Air Force | Government |
Suneva Medical, Inc.
Suneva Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Suneva Medical, Inc. develops, manufactures and commercializes novel, differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. It offers ArteFill, ReFissa, Bellafill, and ReGenica Skincare products. The company is headquartered in San Diego, CA. | Electronic Technology |
SpineOvations, Inc.
SpineOvations, Inc. Medical SpecialtiesHealth Technology SpineOvations, Inc. operates as a clinical-stage medical device company. It develops therapies to treat low back pain. The company was founded by Neville Alleyne and is headquartered in Carlsbad, CA. | Health Technology |
